secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0000950170-23-014788
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics Q1 net loss $19.5M; VK2735 shows up to 7.8% weight loss
---------------------------------------------------------------------------

- Net loss $19.5M ($0.25/sh) vs $16.1M ($0.21/sh) in Q1 2022; R&D $11.0M, G&A $9.5M.
- Cash and investments $135.7M at March 31; pro forma with $287.5M offering totals ~$406M.
- VK2735 Phase 1: up to 7.8% mean weight loss from baseline (6% placebo-adjusted); half-life 170-250h; no discontinuations for GI AEs.
- Phase 2b VOYAGE study of VK2809 for NASH fully enrolled; primary endpoint data expected in Q2 2023.
- Phase 1 oral formulation of VK2735 initiated; data expected 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/0000950170-23-014788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/vktx-20230426.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-014788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer